Framework launched to strengthen CGT trials in UK
A new national framework designed to support the standardisation and expansion of advanced therapy clinical trials in the United Kingdom …
Post
-
-
Clinical Trials Day 2026: ‘Research Rising’ theme reflected in Q1 study growth
As 20 May marks Clinical Trials Day 2026, the ‘Research Rising’ theme has never seemed so apt, as trial initiations …
-
Relay Therapeutics reports initial findings from Phase II ReInspire trial
Relay Therapeutics has reported initial findings from its Phase II ReInspire trial evaluating zovegalisib in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic …
-
BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint
BioMarin Pharmaceutical has reported that its pivotal Phase III ENERGY 3 trial assessing BMN 401 in children aged one to …
-
Podcast: Experience as a patient in a first-in-human clinical trial
Today, 20 May, marks Clinical Trials Day. This year's theme, set by the Association of Clinical Research Professionals (ACRP), is "Research …
-
Podcast: Experience as a patient in a first-in-human clinical trial
Today, 20 May, marks Clinical Trials Day. This year's theme, set by the Association of Clinical Research Professionals (ACRP), is "Research …
-
What happens when protocol data finally flows
Rob DiCicco, vice president of portfolio management, and Bill Illis, workstream leader, digital data flow at TransCelerate BioPharma, highlight the advantages of …
-
H1 2026 clinical trials: China, funding and technology set the agenda
As we approach the end of H1, experts have shared their views on the main trends impacting clinical trials in …
-
Boston Scientific’s coronary IVL catheter hits primary endpoints in trial
Boston Scientific has shared positive pivotal trial results for its SEISMIQ 4CE Coronary intravascular lithotripsy (IVL) catheter in treating calcified …
-
Vincentage Pharma touts Phase III win for oral GLP-1RA
China-based Vincentage Pharma is hot on Eli Lilly and Novo Nordisk’s heels after its oral glucagon-like peptide-1 receptor agonist (GLP-1RA) …
-
Design Therapeutics reports Phase I/II RESTORE-FA trial outcomes
Design Therapeutics has reported data from the ongoing Phase I/II RESTORE-FA clinical trial assessing DT-216P2 in Friedreich ataxia (FA) patients. The …
-
First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial
Triveni Bio has dosed the first healthy volunteers in its Phase I study of TRIV-573, a half-life extended bispecific antibody …
-
Protara’s cell therapy shows treatment durability in mid-stage NMIBC study
Protara Therapeutics’ solid tumour-focused cell therapy, TARA-002, has demonstrated its potential to elicit a durable response in patients with non-muscle …
-
AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma?
On 30 May, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, AstraZeneca will release the …
-
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial
MSD’s TROP2-directed antibody-drug conjugate (ADC), sac-TMT, has shown benefit in both overall survival (OS) and progression-free survival (PFS) in a …
